Skip navigation

Neurological products and therapies news

Latest news from Renishaw in the neurosurgical field

Latest articles

  • Renishaw announces completion of the main part of a multi-centre clinical trial jointly undertaken with Herantis Pharma plc for the treatment of Parkinson’s Disease patients

    Renishaw's novel intraparenchymal drug delivery system Global engineering technologies company, Renishaw, announces that its award-winning intraparenchymal drug delivery device, has played a critical role in a joint Phase 1-2 clinical study with Herantis Pharma plc, for the investigation of cerebral dopamine neurotrophic factor (CDNF) as a treatment for Parkinson's disease.

  • Renishaw promotes robotic stereoelectroencephalography (SEEG) at ILAE

    Microdeep depth electrode From 2-4 October 2019, global engineering technologies company, Renishaw, is attending the International League Against Epilepsy’s (ILAE) Annual Scientific Meeting. Attendees can visit Renishaw’s stand to find out more about the benefits of robotic SEEG. The conference will take place in The Birmingham Conferences & Events Centre, Birmingham, UK.

  • Renishaw’s neuroinfuse™ drug delivery system shortlisted for Healthcare Award

    neuroinfuse drug delivery system port and application set A novel drug delivery system that aims to enable pharmaceuticals to bypass the blood-brain barrier for the ongoing treatment of neurological disorders and brain tumours has been shortlisted for the TCT Healthcare Award. Global engineering company, Renishaw, designed and manufactured the device, which includes a metal 3D printed titanium port. The awards will be presented during the TCT Show which takes place at the NEC, Birmingham, UK, on September 25th.

  • Renishaw's neuromate® robot helps deliver deep brain stimulation (DBS) to world's youngest patient

    Renishaw neuromate® robot with neurolocate™ module The youngest patient in the world to receive deep brain stimulation (DBS) has undergone surgery at Evelina London Children’s Hospital, London. The aim of the procedure was to help the patient, Viktoria Kaftanikaite, who was just two years old, to manage her symptoms of dystonia. The procedure was carried out in partnership with King’s College Hospital, London and with assistance from Renishaw’s neuromate stereotactic robot.

  • Engineering innovation brings hope for a Parkinson's cure

    Drug delivery device GDNF trial credit Chris Marshall Mint Motion Global engineering company Renishaw has built a device that has been used in a ground-breaking clinical trial. Manufactured by Renishaw on behalf of the North Bristol NHS Trust, the device enabled the precise delivery of a new drug candidate, Glial Cell Line Derived Neurotrophic Factor (GDNF) with the hope of regenerating dying dopamine brain cells in people with Parkinson’s and thereby improve their symptoms.

All articles